Acutus Medical Inc. (AFIB) News
Filter AFIB News Items
AFIB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AFIB News Highlights
- For AFIB, its 30 day story count is now at 4.
- Over the past 11 days, the trend for AFIB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AFIB are PEAK.
Latest AFIB News From Around the Web
Below are the latest news stories about ACUTUS MEDICAL INC that investors may wish to consider to help them evaluate AFIB as an investment opportunity.
Acutus Medical Inc. (NASDAQ: AFIB) Slid -8.96% In 6 Months Getting Ready For What’s NextAcutus Medical Inc. (NASDAQ:AFIB)’s traded shares stood at 0.31 million during the last session. At the close of trading, the stock’s price was $1.22, to imply an increase of 18.45% or $0.19 in intraday trading. The AFIB share’s 52-week high remains $3.16, putting it -159.02% down since that peak but still an impressive 60.66% since … Acutus Medical Inc. (NASDAQ: AFIB) Slid -8.96% In 6 Months Getting Ready For What’s Next Read More » |
Acutus Medical, Inc.: Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial OfficerCARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmi… |
Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial OfficerCARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company |
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CARLSBAD, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on January 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 2 individuals hired by Acutus in December 2022. The equity aw |
Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF SymposiumCARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session a |
Looking Into Acutus Medical''s Return On Capital EmployedAcutus Medical (NASDAQ: AFIB ) brought in sales totaling $3.64 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 457.21%, resulting in a loss of $20.43 million. In Q2, Acutus Medical earned $5.72 million, and total sales reached $4.08 million. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is … Full story available on Benzinga.com |
Acutus stock rises as Medtronic to pay $17M milestone under heart device pactAcutus Medical (AFIB) said it will get a $17M milestone payment from Medtronic (MDT) as a submission for CE Mark in the EU was undertaken for its left-heart access portfolio.Acutus… |
Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to MedtronicCARLSBAD, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of its left-heart access portfolio with the submission for CE Mark of this portfolio under European Union (EU) Medical Device Regulations (MDR). This milesto |
Acutus Medical Announces Full Market Release of next generation software platform AcQMap 8.5Software improvements further leverage the system’s unique ultrasound capabilities for non-contact anatomy reconstruction Software improvements further leverage the system’s unique ultrasound capabilities for non-contact anatomy reconstruction |
Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping CatheterThe flagship 3D mapping catheter from Acutus Medical has been certified under the new European Medical Device RegulationsCARLSBAD, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or “the Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced receipt of a CE Mark issued under the European Union (EU) Medical Device Regulations (MDR) for its AcQMap 3D Imaging and Mapping Catheter |